Structured Review

BioreclamationIVT human peripheral blood mononuclear cells pbmc
Human Peripheral Blood Mononuclear Cells Pbmc, supplied by BioreclamationIVT, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human peripheral blood mononuclear cells pbmc/product/BioreclamationIVT
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
human peripheral blood mononuclear cells pbmc - by Bioz Stars, 2020-09
93/100 stars

Images

Related Articles

other:

Article Title: Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico
Article Snippet: Materials Human colorectal cancer cells, HCT 116 and HT-29, were purchased from the American Type Culture Collection (Manassas, Virginia) and human peripheral blood mononuclear cells (PBMC) from BioIVT (Hicksville, New York).

Transmigration Assay:

Article Title: 12/15-Lipoxygenase-dependent ROS production is required for diet-induced endothelial barrier dysfunction
Article Snippet: .. Human peripheral blood mononuclear cells (PBMCs) were purchased from BioreclamationIVT (Baltimore, MD), suspended in RPMI 1640 medium containing 50 μM 2-mercaptoethanol, 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin and used in transmigration assays. .. Cultures were maintained at 37°C in a humidified 95% air and 5% CO2 atmosphere.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    BioreclamationIVT pbmc
    Dose-dependent depletion by daratumumab of plasma cells and plasmablasts from peripheral blood mononuclear cell <t>(PBMC)</t> samples ex vivo. a Representative fluorescence-activated cell sorting (FACS) plot of combined plasma cells/plasmablasts. Shown is pre-gated on live singlet CD3 − CD56 − CD19 low/mid CD20 − lymphocytes. From left to right, plot shows the representative plasma cell/plasmablast population at 1 μg/ml isotype control, 0.0003 μg/ml daratumumab, 0.01 μg/ml daratumumab and 1 μg/ml daratumumab (Dara), respectively. Number in the quadrant shows absolute number of CD27 hi <t>CD38</t> hi plasma cells-plasmablasts in each condition at 72 h post-culture. b Quantification of plasma cell/plasmablast number at 72 h post-culture with isotype control or daratumumab at indicated concentrations. c Dose-response of plasma cell/plasmablast depletion by daratumumab in all donors with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) and healthy donors combined. d Representative FACS plot of CD27 − IgD − memory B cell, CD27 + IgD − class-switched memory B cell and CD27 + IgD + non-class-switched memory B cell at 72 h post-culture in the presence of daratumumab at each indicated concentration. Number in the quadrant shows absolute number of each memory B cell subset. e - g Slight increase in non-class-switched memory B cell ( e ), CD27 + class-switched memory B cell ( f ) and CD27 − memory B cell ( g ) compared to isotype control at each indicated concentration. For each individual donor at each daratumumab concentration, triplicate wells were combined for quantification in a , b and d and then normalized to isotype control in c and e - g Data shown represent four healthy controls, five donors with SLE and four with RA
    Pbmc, supplied by BioreclamationIVT, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbmc/product/BioreclamationIVT
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pbmc - by Bioz Stars, 2020-09
    92/100 stars
      Buy from Supplier

    91
    BioreclamationIVT african green monkey peripheral blood mononuclear cells pbmcs
    Binding of 4945_G06 to <t>CD4-expressing</t> peripheral blood mononuclear cells <t>(PBMCs)</t> of various species. PBMCs were obtained from whole blood from each of the indicated species. 4945_G06 was incubated in a titration series with cells, and binding was detected with a fluorescently labeled anti-His tag antibody by FACS. CD3 + /CD8 − cells (presumed to be CD4 + ) were gated using species-matched antibodies (see Materials and Methods). Strong binding to human PBMCs and weak binding ( > 500-fold less) to cynomolgus monkey PBMCs were observed, with no binding to marmoset, African Green monkey, or murine PBMCs being observed. The average signal from duplicates is plotted, with 4-parameter best-fit curves being shown. MFI, mean fluorescence intensity.
    African Green Monkey Peripheral Blood Mononuclear Cells Pbmcs, supplied by BioreclamationIVT, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/african green monkey peripheral blood mononuclear cells pbmcs/product/BioreclamationIVT
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    african green monkey peripheral blood mononuclear cells pbmcs - by Bioz Stars, 2020-09
    91/100 stars
      Buy from Supplier

    88
    BioreclamationIVT rhesus monkey pbmc
    Binding of 4945_G06 to <t>CD4-expressing</t> peripheral blood mononuclear cells <t>(PBMCs)</t> of various species. PBMCs were obtained from whole blood from each of the indicated species. 4945_G06 was incubated in a titration series with cells, and binding was detected with a fluorescently labeled anti-His tag antibody by FACS. CD3 + /CD8 − cells (presumed to be CD4 + ) were gated using species-matched antibodies (see Materials and Methods). Strong binding to human PBMCs and weak binding ( > 500-fold less) to cynomolgus monkey PBMCs were observed, with no binding to marmoset, African Green monkey, or murine PBMCs being observed. The average signal from duplicates is plotted, with 4-parameter best-fit curves being shown. MFI, mean fluorescence intensity.
    Rhesus Monkey Pbmc, supplied by BioreclamationIVT, used in various techniques. Bioz Stars score: 88/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rhesus monkey pbmc/product/BioreclamationIVT
    Average 88 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    rhesus monkey pbmc - by Bioz Stars, 2020-09
    88/100 stars
      Buy from Supplier

    Image Search Results


    Dose-dependent depletion by daratumumab of plasma cells and plasmablasts from peripheral blood mononuclear cell (PBMC) samples ex vivo. a Representative fluorescence-activated cell sorting (FACS) plot of combined plasma cells/plasmablasts. Shown is pre-gated on live singlet CD3 − CD56 − CD19 low/mid CD20 − lymphocytes. From left to right, plot shows the representative plasma cell/plasmablast population at 1 μg/ml isotype control, 0.0003 μg/ml daratumumab, 0.01 μg/ml daratumumab and 1 μg/ml daratumumab (Dara), respectively. Number in the quadrant shows absolute number of CD27 hi CD38 hi plasma cells-plasmablasts in each condition at 72 h post-culture. b Quantification of plasma cell/plasmablast number at 72 h post-culture with isotype control or daratumumab at indicated concentrations. c Dose-response of plasma cell/plasmablast depletion by daratumumab in all donors with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) and healthy donors combined. d Representative FACS plot of CD27 − IgD − memory B cell, CD27 + IgD − class-switched memory B cell and CD27 + IgD + non-class-switched memory B cell at 72 h post-culture in the presence of daratumumab at each indicated concentration. Number in the quadrant shows absolute number of each memory B cell subset. e - g Slight increase in non-class-switched memory B cell ( e ), CD27 + class-switched memory B cell ( f ) and CD27 − memory B cell ( g ) compared to isotype control at each indicated concentration. For each individual donor at each daratumumab concentration, triplicate wells were combined for quantification in a , b and d and then normalized to isotype control in c and e - g Data shown represent four healthy controls, five donors with SLE and four with RA

    Journal: Arthritis Research & Therapy

    Article Title: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

    doi: 10.1186/s13075-018-1578-z

    Figure Lengend Snippet: Dose-dependent depletion by daratumumab of plasma cells and plasmablasts from peripheral blood mononuclear cell (PBMC) samples ex vivo. a Representative fluorescence-activated cell sorting (FACS) plot of combined plasma cells/plasmablasts. Shown is pre-gated on live singlet CD3 − CD56 − CD19 low/mid CD20 − lymphocytes. From left to right, plot shows the representative plasma cell/plasmablast population at 1 μg/ml isotype control, 0.0003 μg/ml daratumumab, 0.01 μg/ml daratumumab and 1 μg/ml daratumumab (Dara), respectively. Number in the quadrant shows absolute number of CD27 hi CD38 hi plasma cells-plasmablasts in each condition at 72 h post-culture. b Quantification of plasma cell/plasmablast number at 72 h post-culture with isotype control or daratumumab at indicated concentrations. c Dose-response of plasma cell/plasmablast depletion by daratumumab in all donors with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) and healthy donors combined. d Representative FACS plot of CD27 − IgD − memory B cell, CD27 + IgD − class-switched memory B cell and CD27 + IgD + non-class-switched memory B cell at 72 h post-culture in the presence of daratumumab at each indicated concentration. Number in the quadrant shows absolute number of each memory B cell subset. e - g Slight increase in non-class-switched memory B cell ( e ), CD27 + class-switched memory B cell ( f ) and CD27 − memory B cell ( g ) compared to isotype control at each indicated concentration. For each individual donor at each daratumumab concentration, triplicate wells were combined for quantification in a , b and d and then normalized to isotype control in c and e - g Data shown represent four healthy controls, five donors with SLE and four with RA

    Article Snippet: PBMC samples for CD38 expression analysis from patients with SLE and RA and from healthy donors were acquired from Bioreclamation (Westbury, NY, USA) and Precision for Medicine (Frederick, MD, USA).

    Techniques: Ex Vivo, Fluorescence, FACS, Concentration Assay

    CD38 expression on immune cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). a Gating strategy for plasma cells and plasmablasts in PBMC samples. Plasma cells are gated as live singlet lymphocytes, CD3 − CD56 − CD19 low/mid CD20 − CD38 hi CD27 hi CD138 + . Plasmablasts are gated as live singlet lymphocytes, CD3 − CD56 − CD19 low/mid CD20 − CD38 hi CD27 hi CD138 − . CD19 hi B cells are separated into naïve B cell (IgD + CD27 − ), non-class-switched memory B cell (CD27 + IgD + ), class-switched memory B cell (CD27 + IgD − ) and CD27 − memory B cell (CD27 − IgD − ). b Percentage of CD27 hi CD38 hi CD138 + plasma cells in total lymphocytes from PBMCs from healthy controls and patients with SLE or RA. c Percentage of CD27 hi CD38 hi CD138 − plasmablasts in total lymphocytes from PBMCs from different groups. d-f Percentage of class-switched memory cell ( d ), CD27 − memory B cell ( e ), and non-class-switched memory B cell ( f ) in total lymphocytes. g Quantification of CD38 MFI in naïve B cell, non-class switched memory cell, class-switched memory cell, CD27 − memory cell, plasma cells and plasmablasts

    Journal: Arthritis Research & Therapy

    Article Title: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

    doi: 10.1186/s13075-018-1578-z

    Figure Lengend Snippet: CD38 expression on immune cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). a Gating strategy for plasma cells and plasmablasts in PBMC samples. Plasma cells are gated as live singlet lymphocytes, CD3 − CD56 − CD19 low/mid CD20 − CD38 hi CD27 hi CD138 + . Plasmablasts are gated as live singlet lymphocytes, CD3 − CD56 − CD19 low/mid CD20 − CD38 hi CD27 hi CD138 − . CD19 hi B cells are separated into naïve B cell (IgD + CD27 − ), non-class-switched memory B cell (CD27 + IgD + ), class-switched memory B cell (CD27 + IgD − ) and CD27 − memory B cell (CD27 − IgD − ). b Percentage of CD27 hi CD38 hi CD138 + plasma cells in total lymphocytes from PBMCs from healthy controls and patients with SLE or RA. c Percentage of CD27 hi CD38 hi CD138 − plasmablasts in total lymphocytes from PBMCs from different groups. d-f Percentage of class-switched memory cell ( d ), CD27 − memory B cell ( e ), and non-class-switched memory B cell ( f ) in total lymphocytes. g Quantification of CD38 MFI in naïve B cell, non-class switched memory cell, class-switched memory cell, CD27 − memory cell, plasma cells and plasmablasts

    Article Snippet: PBMC samples for CD38 expression analysis from patients with SLE and RA and from healthy donors were acquired from Bioreclamation (Westbury, NY, USA) and Precision for Medicine (Frederick, MD, USA).

    Techniques: Expressing

    CD38 expression on myeloid, natural killer (NK) and T cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). a Quantification of CD38 MFI on CD56 + CD16 + NK cells, CD11c + classical DC, and BDCA2 + plasmacytoid dendritic cells (DC). b Quantification of CD38 MFI on CD45RA + naïve T cells, CD62L hi CD27 hi CCR7 + CD45RA − central memory T cells (T CM ) and CD62L − CD45RA − effector memory T cell (T EM ). c Representative fluorescence-activated cell sorting (FACS) plot of CD38 expression on CD4 + CD127 low CD25 hi T regulatory cells (Tregs). d Proportion of the CD38 bri subset in peripheral Tregs from healthy controls and donors with SLE or RA

    Journal: Arthritis Research & Therapy

    Article Title: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

    doi: 10.1186/s13075-018-1578-z

    Figure Lengend Snippet: CD38 expression on myeloid, natural killer (NK) and T cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). a Quantification of CD38 MFI on CD56 + CD16 + NK cells, CD11c + classical DC, and BDCA2 + plasmacytoid dendritic cells (DC). b Quantification of CD38 MFI on CD45RA + naïve T cells, CD62L hi CD27 hi CCR7 + CD45RA − central memory T cells (T CM ) and CD62L − CD45RA − effector memory T cell (T EM ). c Representative fluorescence-activated cell sorting (FACS) plot of CD38 expression on CD4 + CD127 low CD25 hi T regulatory cells (Tregs). d Proportion of the CD38 bri subset in peripheral Tregs from healthy controls and donors with SLE or RA

    Article Snippet: PBMC samples for CD38 expression analysis from patients with SLE and RA and from healthy donors were acquired from Bioreclamation (Westbury, NY, USA) and Precision for Medicine (Frederick, MD, USA).

    Techniques: Expressing, Fluorescence, FACS

    Dose-dependent depletion by daratumumab of plasma cells and plasmablasts from peripheral blood mononuclear cell (PBMC) samples ex vivo. a Representative fluorescence-activated cell sorting (FACS) plot of combined plasma cells/plasmablasts. Shown is pre-gated on live singlet CD3 − CD56 − CD19 low/mid CD20 − lymphocytes. From left to right, plot shows the representative plasma cell/plasmablast population at 1 μg/ml isotype control, 0.0003 μg/ml daratumumab, 0.01 μg/ml daratumumab and 1 μg/ml daratumumab (Dara), respectively. Number in the quadrant shows absolute number of CD27 hi CD38 hi plasma cells-plasmablasts in each condition at 72 h post-culture. b Quantification of plasma cell/plasmablast number at 72 h post-culture with isotype control or daratumumab at indicated concentrations. c Dose-response of plasma cell/plasmablast depletion by daratumumab in all donors with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) and healthy donors combined. d Representative FACS plot of CD27 − IgD − memory B cell, CD27 + IgD − class-switched memory B cell and CD27 + IgD + non-class-switched memory B cell at 72 h post-culture in the presence of daratumumab at each indicated concentration. Number in the quadrant shows absolute number of each memory B cell subset. e - g Slight increase in non-class-switched memory B cell ( e ), CD27 + class-switched memory B cell ( f ) and CD27 − memory B cell ( g ) compared to isotype control at each indicated concentration. For each individual donor at each daratumumab concentration, triplicate wells were combined for quantification in a , b and d and then normalized to isotype control in c and e - g Data shown represent four healthy controls, five donors with SLE and four with RA

    Journal: Arthritis Research & Therapy

    Article Title: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

    doi: 10.1186/s13075-018-1578-z

    Figure Lengend Snippet: Dose-dependent depletion by daratumumab of plasma cells and plasmablasts from peripheral blood mononuclear cell (PBMC) samples ex vivo. a Representative fluorescence-activated cell sorting (FACS) plot of combined plasma cells/plasmablasts. Shown is pre-gated on live singlet CD3 − CD56 − CD19 low/mid CD20 − lymphocytes. From left to right, plot shows the representative plasma cell/plasmablast population at 1 μg/ml isotype control, 0.0003 μg/ml daratumumab, 0.01 μg/ml daratumumab and 1 μg/ml daratumumab (Dara), respectively. Number in the quadrant shows absolute number of CD27 hi CD38 hi plasma cells-plasmablasts in each condition at 72 h post-culture. b Quantification of plasma cell/plasmablast number at 72 h post-culture with isotype control or daratumumab at indicated concentrations. c Dose-response of plasma cell/plasmablast depletion by daratumumab in all donors with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) and healthy donors combined. d Representative FACS plot of CD27 − IgD − memory B cell, CD27 + IgD − class-switched memory B cell and CD27 + IgD + non-class-switched memory B cell at 72 h post-culture in the presence of daratumumab at each indicated concentration. Number in the quadrant shows absolute number of each memory B cell subset. e - g Slight increase in non-class-switched memory B cell ( e ), CD27 + class-switched memory B cell ( f ) and CD27 − memory B cell ( g ) compared to isotype control at each indicated concentration. For each individual donor at each daratumumab concentration, triplicate wells were combined for quantification in a , b and d and then normalized to isotype control in c and e - g Data shown represent four healthy controls, five donors with SLE and four with RA

    Article Snippet: PBMC samples for CD38 expression analysis from patients with SLE and RA and from healthy donors were acquired from Bioreclamation (Westbury, NY, USA) and Precision for Medicine (Frederick, MD, USA).

    Techniques: Ex Vivo, Fluorescence, FACS, Concentration Assay

    CD38 expression on immune cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). a Gating strategy for plasma cells and plasmablasts in PBMC samples. Plasma cells are gated as live singlet lymphocytes, CD3 − CD56 − CD19 low/mid CD20 − CD38 hi CD27 hi CD138 + . Plasmablasts are gated as live singlet lymphocytes, CD3 − CD56 − CD19 low/mid CD20 − CD38 hi CD27 hi CD138 − . CD19 hi B cells are separated into naïve B cell (IgD + CD27 − ), non-class-switched memory B cell (CD27 + IgD + ), class-switched memory B cell (CD27 + IgD − ) and CD27 − memory B cell (CD27 − IgD − ). b Percentage of CD27 hi CD38 hi CD138 + plasma cells in total lymphocytes from PBMCs from healthy controls and patients with SLE or RA. c Percentage of CD27 hi CD38 hi CD138 − plasmablasts in total lymphocytes from PBMCs from different groups. d-f Percentage of class-switched memory cell ( d ), CD27 − memory B cell ( e ), and non-class-switched memory B cell ( f ) in total lymphocytes. g Quantification of CD38 MFI in naïve B cell, non-class switched memory cell, class-switched memory cell, CD27 − memory cell, plasma cells and plasmablasts

    Journal: Arthritis Research & Therapy

    Article Title: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

    doi: 10.1186/s13075-018-1578-z

    Figure Lengend Snippet: CD38 expression on immune cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). a Gating strategy for plasma cells and plasmablasts in PBMC samples. Plasma cells are gated as live singlet lymphocytes, CD3 − CD56 − CD19 low/mid CD20 − CD38 hi CD27 hi CD138 + . Plasmablasts are gated as live singlet lymphocytes, CD3 − CD56 − CD19 low/mid CD20 − CD38 hi CD27 hi CD138 − . CD19 hi B cells are separated into naïve B cell (IgD + CD27 − ), non-class-switched memory B cell (CD27 + IgD + ), class-switched memory B cell (CD27 + IgD − ) and CD27 − memory B cell (CD27 − IgD − ). b Percentage of CD27 hi CD38 hi CD138 + plasma cells in total lymphocytes from PBMCs from healthy controls and patients with SLE or RA. c Percentage of CD27 hi CD38 hi CD138 − plasmablasts in total lymphocytes from PBMCs from different groups. d-f Percentage of class-switched memory cell ( d ), CD27 − memory B cell ( e ), and non-class-switched memory B cell ( f ) in total lymphocytes. g Quantification of CD38 MFI in naïve B cell, non-class switched memory cell, class-switched memory cell, CD27 − memory cell, plasma cells and plasmablasts

    Article Snippet: PBMC samples for CD38 expression analysis from patients with SLE and RA and from healthy donors were acquired from Bioreclamation (Westbury, NY, USA) and Precision for Medicine (Frederick, MD, USA).

    Techniques: Expressing

    CD38 expression on myeloid, natural killer (NK) and T cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). a Quantification of CD38 MFI on CD56 + CD16 + NK cells, CD11c + classical DC, and BDCA2 + plasmacytoid dendritic cells (DC). b Quantification of CD38 MFI on CD45RA + naïve T cells, CD62L hi CD27 hi CCR7 + CD45RA − central memory T cells (T CM ) and CD62L − CD45RA − effector memory T cell (T EM ). c Representative fluorescence-activated cell sorting (FACS) plot of CD38 expression on CD4 + CD127 low CD25 hi T regulatory cells (Tregs). d Proportion of the CD38 bri subset in peripheral Tregs from healthy controls and donors with SLE or RA

    Journal: Arthritis Research & Therapy

    Article Title: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

    doi: 10.1186/s13075-018-1578-z

    Figure Lengend Snippet: CD38 expression on myeloid, natural killer (NK) and T cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). a Quantification of CD38 MFI on CD56 + CD16 + NK cells, CD11c + classical DC, and BDCA2 + plasmacytoid dendritic cells (DC). b Quantification of CD38 MFI on CD45RA + naïve T cells, CD62L hi CD27 hi CCR7 + CD45RA − central memory T cells (T CM ) and CD62L − CD45RA − effector memory T cell (T EM ). c Representative fluorescence-activated cell sorting (FACS) plot of CD38 expression on CD4 + CD127 low CD25 hi T regulatory cells (Tregs). d Proportion of the CD38 bri subset in peripheral Tregs from healthy controls and donors with SLE or RA

    Article Snippet: PBMC samples for CD38 expression analysis from patients with SLE and RA and from healthy donors were acquired from Bioreclamation (Westbury, NY, USA) and Precision for Medicine (Frederick, MD, USA).

    Techniques: Expressing, Fluorescence, FACS

    Binding of 4945_G06 to CD4-expressing peripheral blood mononuclear cells (PBMCs) of various species. PBMCs were obtained from whole blood from each of the indicated species. 4945_G06 was incubated in a titration series with cells, and binding was detected with a fluorescently labeled anti-His tag antibody by FACS. CD3 + /CD8 − cells (presumed to be CD4 + ) were gated using species-matched antibodies (see Materials and Methods). Strong binding to human PBMCs and weak binding ( > 500-fold less) to cynomolgus monkey PBMCs were observed, with no binding to marmoset, African Green monkey, or murine PBMCs being observed. The average signal from duplicates is plotted, with 4-parameter best-fit curves being shown. MFI, mean fluorescence intensity.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity

    doi: 10.1128/AAC.00508-17

    Figure Lengend Snippet: Binding of 4945_G06 to CD4-expressing peripheral blood mononuclear cells (PBMCs) of various species. PBMCs were obtained from whole blood from each of the indicated species. 4945_G06 was incubated in a titration series with cells, and binding was detected with a fluorescently labeled anti-His tag antibody by FACS. CD3 + /CD8 − cells (presumed to be CD4 + ) were gated using species-matched antibodies (see Materials and Methods). Strong binding to human PBMCs and weak binding ( > 500-fold less) to cynomolgus monkey PBMCs were observed, with no binding to marmoset, African Green monkey, or murine PBMCs being observed. The average signal from duplicates is plotted, with 4-parameter best-fit curves being shown. MFI, mean fluorescence intensity.

    Article Snippet: The cross-reactivity of the anti-CD4 Adnectin was assessed on human, cynomolgus monkey, marmoset, and African green monkey peripheral blood mononuclear cells (PBMCs) (all nonhuman primate tissues were sourced from BioReclamation) and murine PBMCs.

    Techniques: Binding Assay, Expressing, Incubation, Titration, Labeling, FACS, Fluorescence